Gabelli analyst Kevin Kedra initiated Elanco (ELAN) with a Buy rating and 2020 private market value estimate of $32 per share, stating that he views the animal health market as attractive given that it is predominately cash-pay with lower development costs and longer product life cycles than human health. The operating margins at Elanco, which is a carve-out of parent Eli Lilly (LLY) expected to go public on September 20, lag the industry leader and Kedra sees a significant opportunity for margin expansion, he tells investors.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.